|
|||||
|
|
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study |
|
| Authors: | Egilius L. H. Spierings MD PhD Xiaoping Ning MD MS Verena Ramirez Campos MD Joshua M. Cohen MD MPH FAHS Steve Barash PhD Dawn C. Buse PhD |
| Affiliation: | 1. Boston Headache Institute & MedVadis Research Corporation, Waltham, MA, USA;2. Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA;3. Department of Neurology, Albert Einstein College of Medicine, New York, NY, USA |
| Abstract: | |
| Keywords: | calcitonin gene-related peptide migraine Migraine-Specific Quality of Life monoclonal antibody Work Productivity and Activity Impairment |